Daiwa Securities Group Inc. Nektar Therapeutics Transaction History

Daiwa Securities Group Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 03, 2022	SELL	$10.83 - $18.41 $985 - $1,675	-91 Reduced 14.44%	539 $7,000
Q3 2021 Nov 05, 2021	BUY	$13.07 - $18.84 $3,515 - $5,067	269 Added 74.52%	630 $11,000
Q1 2021 May 03, 2021	BUY	$16.56 - $25.46 $397 - $611	24 Added 7.12%	361 $7,000
Q4 2020 Feb 04, 2021	SELL	$15.77 - $19.03 $10,345 - $12,483	-656 Reduced 66.06%	337 $6,000
Q4 2019 Jan 31, 2020	SELL	$15.87 - $23.12 $108,344 - $157,840	-6,827 Reduced 87.3%	993 $21,000
Q3 2019 Nov 04, 2019	BUY	$16.91 - $36.27 $9,300 - $19,948	550 Added 7.57%	7,820 $142,000
Q2 2019 Jul 24, 2019	SELL	$31.0 - $36.3 $744 - $871	-24 Reduced 0.33%	7,270 $259,000
Q4 2018 Feb 05, 2019	BUY	$30.43 - $56.65 $7,607 - $14,162	250 Added 3.55%	7,294 $240,000
Q3 2018 Nov 01, 2018	BUY	$46.46 - $68.49 $23,230 - $34,245	500 Added 7.64%	7,044 $429,000
Q2 2018 Jul 30, 2018	BUY	$46.25 - $104.45 $254,421 - $574,579	5,501 Added 527.42%	6,544 $320,000
Q1 2018 May 02, 2018	BUY	$57.4 - $108.44 $59,868 - $113,102	1,043 New	1,043 $111,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

Stay updated on Daiwa Securities Group Inc. with notifications on news.